Atrial fibrillation in heart failure: high mortality risk even if ventricular function is preserved

Ratika Parkash1, William H Maisel, F Michael Toca

  • 1Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada. ratica.parkash@cdha.nshealth.ca

American Heart Journal
|October 8, 2005
PubMed

Insights

Patients with atrial fibrillation (AF) and heart failure (HF) with preserved ejection fraction (EF) face high mortality, similar to those with depressed EF. Further research is needed to understand prognosis and treatment impacts.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Public Health

Background:

  • Atrial fibrillation (AF) and heart failure (HF) are common conditions.
  • Prognosis in patients with both AF and HF is influenced by left ventricular (LV) systolic function, specifically ejection fraction (EF).

Purpose of the Study:

  • To investigate whether patients with AF and HF have a better prognosis when systolic function is preserved (EF > 50%) compared to those with depressed systolic function.

Main Methods:

  • Retrospective review of 478 patients diagnosed with AF and HF between January 1997 and December 2002.
  • Ejection fraction (EF) was measured, and patient vital status was determined using the Social Security Death Index.

Main Results:

  • 46% of patients had preserved EF (> 50%).
  • Preserved EF group was older, had more women, and a higher prevalence of hypertension and pulmonary disease.
  • Five-year mortality was similar between preserved (50%) and depressed (48%) EF groups.
  • Multivariable analysis identified age > 75, cancer, cerebrovascular disease, aortic valve disease, elevated creatinine, and low sodium as mortality predictors.
  • Beta-blockers and ACE inhibitors/ARBs were associated with lower mortality.

Conclusions:

  • Patients presenting with AF, HF, and preserved LVEF have a high mortality rate, comparable to those with depressed LVEF.
  • Further investigation is required to evaluate the impact of specific therapies and elucidate the factors contributing to the poor prognosis in this patient cohort.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...